IL-6/JAK/STAT3 signaling strongly inhibits anti-tumor immune response through negative regulatory effects of T cells and natural killer cells, which contributes to the formation of primary immunotherapy resistance (Johnson et al. 2018). Here, IL6 is linked to neoplasm.